2151032-62-9
2151032-62-9 structure
- Name: Cendakimab
- Chemical Name: Cendakimab
- CAS Number: 2151032-62-9
- Molecular Formula:
- Molecular Weight:
- Catalog: Signaling Pathways Immunology/Inflammation Interleukin Related
- Create Date: 2023-01-26 19:48:46
- Modify Date: 2024-01-02 19:02:50
-
Cendakimab (RPC4046; ABT 308; CC-93538) is a selective, humanized, recombinant monoclonal antibody against the IL-13 molecule. Cendakimab has a high affinity and potency for both human wild-type and variant IL-13 and blocks binding of IL-13 to both IL-13Rα1 and IL-13Rα2 with IC50s of 352 pM and 631 pM by ELISA, respectively. Cendakimab recognizes both wild-type human IL-13 and the common polymorphic variant R110Q, with binding affinities of 52 and 50 pM, respectively. Cendakimab has the potential for IL-13-related allergic/inflammatory diseases (e.g., asthma and eosinophilic esophagitis)[1].
| Name | Cendakimab |
|---|
| Description | Cendakimab (RPC4046; ABT 308; CC-93538) is a selective, humanized, recombinant monoclonal antibody against the IL-13 molecule. Cendakimab has a high affinity and potency for both human wild-type and variant IL-13 and blocks binding of IL-13 to both IL-13Rα1 and IL-13Rα2 with IC50s of 352 pM and 631 pM by ELISA, respectively. Cendakimab recognizes both wild-type human IL-13 and the common polymorphic variant R110Q, with binding affinities of 52 and 50 pM, respectively. Cendakimab has the potential for IL-13-related allergic/inflammatory diseases (e.g., asthma and eosinophilic esophagitis)[1]. |
|---|---|
| Related Catalog | |
| Target |
IL-13 |
| In Vitro | Cendakimab (RPC4046; ABT 308; CC-93538) fully neutralizes IL-13-induced thymus and activation-regulated chemokine from lung epithelial A-549 cells with potencies ranging from 80 to 513 pM[1]. |
| References |
| No Any Chemical & Physical Properties |